Atlas Trials

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Clinical trial NCT05683171 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05683171
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2023-05-19
Primary completion
2027-09-30
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.